Canada Spends Logo

Explore our Budget 2026 analysis

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

McMaster University

$120,000.00

Biochemical and molecular characterization of anti-platelet factor 4 antibodies in heparin-induced thrombocytopenia

FY 2025-26

Summary
Patients who undergo cardiac surgery or total knee/hip replacements often receive the blood thinner heparin to prevent life-threatening blood clots. However, in some patients, heparin can paradoxically trigger blood clot formation, leading to serious complications such as limb amputation or even death in the most severe cases. This disorder, known as heparin-induced thrombocytopenia (HIT), happens when heparin binds to a naturally occurring protein called platelet factor 4 (PF4), which is then recognized by a patient's immune system as a foreign protein. This causes platelets, which are cells involved in clot formation, to become activated, leading to blood clots. During the COVID-19 pandemic, another related disorder targeting PF4 was discovered, called vaccine-induced immune thrombocytopenia and thrombosis (VITT). VITT is a rare but severe clotting disorder caused by certain adenoviral vector-based vaccines against SARS-CoV-2. Normally, an immune response involves many antibodies against one target, called a polyclonal response. Surprisingly, VITT and related disorders have been shown to be caused by a single type of antibody (monoclonal), representing a highly unusual and rare immune mechanism. Until recently, HIT was also thought to involve a typical polyclonal immune response. However, in our recent New England Journal of Medicine publication, we discovered HIT is actually caused by a monoclonal antibody, similar to other anti-PF4 disorders. The goal of my project is to characterize the differences between individual HIT patient antibodies to improve diagnosis and prevent HIT. This will be accomplished by isolating and characterizing the disease-causing antibodies and testing them in a model that mimics a blood vessel to determine which cells are involved in forming blood clots. By identifying specific targets and mechanisms, this research will improve both diagnostic testing and treatments for HIT, directly benefiting patients and reducing healthcare burden.
Program
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
559296
Name
Treverton Jared
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Biochemical and molecular characterization of anti-platelet factor 4 antibodies in heparin-induced thrombocytopenia
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Antibodies; Cxcl4; Heparin; Platelet Factor 4; Platelets; Thrombocytopenia; Thrombosis
Abstract
Patients who undergo cardiac surgery or total knee/hip replacements often receive the blood thinner heparin to prevent life-threatening blood clots. However, in some patients, heparin can paradoxically trigger blood clot formation, leading to serious complications such as limb amputation or even death in the most severe cases. This disorder, known as heparin-induced thrombocytopenia (HIT), happens when heparin binds to a naturally occurring protein called platelet factor 4 (PF4), which is then recognized by a patient's immune system as a foreign protein. This causes platelets, which are cells involved in clot formation, to become activated, leading to blood clots. During the COVID-19 pandemic, another related disorder targeting PF4 was discovered, called vaccine-induced immune thrombocytopenia and thrombosis (VITT). VITT is a rare but severe clotting disorder caused by certain adenoviral vector-based vaccines against SARS-CoV-2. Normally, an immune response involves many antibodies against one target, called a polyclonal response. Surprisingly, VITT and related disorders have been shown to be caused by a single type of antibody (monoclonal), representing a highly unusual and rare immune mechanism. Until recently, HIT was also thought to involve a typical polyclonal immune response. However, in our recent New England Journal of Medicine publication, we discovered HIT is actually caused by a monoclonal antibody, similar to other anti-PF4 disorders. The goal of my project is to characterize the differences between individual HIT patient antibodies to improve diagnosis and prevent HIT. This will be accomplished by isolating and characterizing the disease-causing antibodies and testing them in a model that mimics a blood vessel to determine which cells are involved in forming blood clots. By identifying specific targets and mechanisms, this research will improve both diagnostic testing and treatments for HIT, directly benefiting patients and reducing healthcare burden.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Treverton, Jared
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~
McMaster University - $120,000 Grant (2025-26) | Canada Spends